Related Experiment Videos

Moyamoya disease with a marked collateral supply through the artery of Bernasconi-Cassinari

I Pascual-Castroviejo1, J Viano, S I Pascual-Pascual

  • 1Service of Pediatric Neurology and Autonoma University, Hospital Infantil 'La Paz', Madrid, Spain.

Brain & Development
|January 1, 1996
PubMed

Insights

This case study highlights moyamoya disease in a young girl, showing early onset and symptom improvement with nicardipine. Magnetic resonance arteriography (MRA) proved superior for detecting intracranial vessel anomalies.

Area of Science:

  • Neurology
  • Vascular Neurology
  • Pediatric Neurology

Background:

  • Moyamoya disease is a rare, progressive cerebrovascular disorder characterized by stenosis of the terminal portion of the internal carotid arteries and the arteries of the circle of Willis.
  • Early diagnosis and intervention are crucial for managing neurological symptoms such as seizures and transient ischemic attacks.

Observation:

  • A 15-year-old female presented with a history of seizures, transient ischemic attacks, and left hemiparesis since 8 months of age.
  • Cerebral arteriography at 1 year revealed moyamoya disease features; a rare embryonic tentorial artery (Bernasconi-Cassinari artery) was noted.
  • This artery was absent at 6 years but reappeared on magnetic resonance arteriography (MRA) at 15 years.

Findings:

  • The fluctuating presence of the Bernasconi-Cassinari artery suggests a very early intrauterine onset of moyamoya disease.
  • Magnetic resonance arteriography (MRA) demonstrated superior capability in detecting intracranial vessel anomalies compared to conventional arteriography.
  • Nicardipine, a calcium channel blocker, combined with antiepileptic drugs, improved both epileptic and neurological symptoms.

Implications:

  • This case underscores the potential for intrauterine onset of moyamoya disease and the diagnostic advantage of MRA in identifying complex vascular anomalies.
  • The findings support the use of calcium channel blockers like nicardipine as an adjunct therapy for managing neurological deficits in moyamoya disease.
  • Further research into the early developmental aspects and advanced imaging techniques for moyamoya disease is warranted.

Related Concept Videos